Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio. Show more

6555 Carnegie Avenue, Cleveland, OH, 44103, United States

https://www.abeonatherapeutics.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

306.1M

52 Wk Range

$4.00 - $7.54

Previous Close

$5.37

Open

$5.32

Volume

1,718,594

Day Range

$5.08 - $5.38

Enterprise Value

168.1M

Cash

168.3M

Avg Qtr Burn

-19.8M

Insider Ownership

16.74%

Institutional Own.

70.54%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ZEVASKYN™ (prademagene zamikeracel) Details Recessive dystrophic epidermolysis bullosa	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABO-102 (AAV-based Gene Therapy) Details Mucopolysaccharidosis type IIIA	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABO-503 (Gene Therapy) Details X-Linked Retinoschisis	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABO-701 (Engineered T-Cell Therapy) Details Advanced Prostate Cancer	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABO-101 (AAV-based Gene Therapy) Details Rare diseases, Rare genetic disease, Genetic disorder, Mucopolysaccharidoses, Mucopolysaccharidosis type IIIB	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.